Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Mealtime faster aspart improves glycaemic control in T1D.
Last updated September 2, 2026
Key finding
Estimated treatment difference [ETD 95% CI] -0.19% [-0.30; -0.09]
This study evaluated the effects of mealtime faster aspart compared to insulin aspart (IAsp) on glycaemic control in individuals with Type 1 Diabetes (T1D) using carbohydrate counting.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of mealtime faster aspart compared to insulin aspart (IAsp) on glycaemic control in individuals with Type 1 Diabetes (T1D) using carbohydrate counting.
Clinical relevance
Improving glycaemic control is crucial for individuals with Type 1 Diabetes to reduce the risk of long-term complications. The significant reduction in HbA1c with mealtime faster aspart suggests that it may be a more effective option for managing blood sugar levels, potentially leading to better health outcomes for patients.
Keep in mind
The study's design may limit generalizability to broader populations. Sample size and participant characteristics were not detailed, affecting applicability. Effectiveness of interventions was unclear for some outcomes.
Published in
Journal Reference
Publication details and source links for this paper.
Ludger R, Takashi K, Thomas RP, et al. For people with T1D using carbohydrate counting, mealtime faster aspart may offer improved glycaemic control versus IAsp. Diabetes Therapy. 2019;10(3):1029-1041. doi:10.1007/s13300-019-0608-4
Main Effects
Mealtime faster aspart significantly reduced HbA1c by -0.19% (p=0.001) compared to IAsp.
Estimated treatment difference for HbA1c was -2.08 mmol/mol (p=0.001) in favor of mealtime faster aspart.
No significant difference in HbA1c reduction was observed with either dose adjustment method.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Insulin aspart, Mealtime faster aspart, Post-meal faster aspart and HbA1c, Reduction in HbA1c levels in MASH responders, Severe hypoglycemia.
This study contributes evidence to
Primary intervention
Insulin aspart
Primary outcomes
- HbA1c
- Reduction in HbA1c levels in MASH responders
- Severe hypoglycemia
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
1
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 59
1
Related topics
5
Evidence pairs
603
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 1 direct semantic evidence topic
Topic contributions
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
HbA1c Reduction
matched_outcome
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerReduction in HbA1c levels in MASH responders
Mealtime faster aspart → Reduction in HbA1c levels in MASH responders
Mealtime faster aspart → Reduction in HbA1c levels in MASH responders
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerSevere hypoglycemia
Mealtime faster aspart → Severe hypoglycemia
Mealtime faster aspart → Severe hypoglycemia
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Mealtime faster aspart reduced HbA1c by -0.19% compared to IAsp.
- Estimated treatment difference was -2.08 mmol/mol in favor of mealtime faster aspart.
- Severe hypoglycaemia rates were similar between treatments.
Who this applies to
- Individuals with Type 1 Diabetes using carbohydrate counting.
- Participants who require mealtime insulin therapy.
Keep in Mind
- Results may not apply to all populations with Type 1 Diabetes.
- Further studies are needed to confirm findings across diverse groups.
- The study did not assess long-term effects of mealtime faster aspart.
Between the Lines
- The study's design may limit generalizability to broader populations.
- Sample size and participant characteristics were not detailed, affecting applicability.
- Effectiveness of interventions was unclear for some outcomes.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Insulin aspart and HbA1c, Insulin aspart and Reduction in HbA1c levels in MASH responders.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Insulin aspart → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
2 studies
outcome_hubMeasures HbA1c as a key outcome.
Insulin aspart Evidence Hub
All studies on Insulin aspart
2 studies
intervention_hubContributes to Insulin aspart evidence base.
Reduction in HbA1c levels in MASH responders Evidence Hub
All studies measuring Reduction in HbA1c levels in MASH responders
1 studies
outcome_hubMeasures Reduction in HbA1c levels in MASH responders as a key outcome.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Insulin aspart and HbA1c
Intervention: Insulin aspartOutcome: HbA1c
2 results
All studies on Insulin aspart and Reduction in HbA1c levels in MASH responders
Intervention: Insulin aspartOutcome: Reduction in HbA1c levels in MASH responders
1 results
All studies on Insulin aspart
Intervention: Insulin aspart
2 results
All studies measuring HbA1c
Outcome: HbA1c
2 results
All studies measuring Reduction in HbA1c levels in MASH responders
Outcome: Reduction in HbA1c levels in MASH responders
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Insulin aspart lower HbA1c?
Moderate Evidence
Insulin aspart may lower HbA1c.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Only one supporting study is available.
Does Mealtime faster aspart lower HbA1c?
Emerging Evidence
Mealtime faster aspart appears to lower HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
What evidence is available on Mealtime faster aspart and reduction in HbA1c levels in mash responders?
Emerging Evidence
Mealtime faster aspart appears to reduce reduction in HbA1c levels in mash responders.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Reduction in HbA1c levels in MASH responders
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Mealtime faster aspart affect severe hypoglycemia?
Emerging Evidence
Current evidence does not show a clear effect of Mealtime faster aspart on severe hypoglycemia.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Severe hypoglycemia
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Semaglutide improves glycemic control more than insulin aspart in type 2 diabetesAdding diabetes medications to metformin improves glycemic control in adults with T2 diabetes.Both insulin adjustment methods effectively lower A1C in type 2 diabetes.Efsitora improves HbA1c control compared to degludec in Japanese adults.Glimepiride increases hypoglycemia risk in type 2 diabetes treatment
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.